Evidence map›Paper›PMID 32070859›Full record

ReviewCurrent opinion in structural biology2020

Allosteric regulation of CRISPR-Cas9 for DNA-targeting and cleavage.

Zhicheng Zuo, Jin Liu

Abstract readReview
In one paragraph

Review in Current opinion in structural biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Flexibility in PAM Recognition Expands DNA Targeting in xCas9.bioRxiv : the preprint server for biology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. The Electronic Structure of Genome Editors from the First Principles.Electronic structure (Bristol, England) · 2023
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhicheng ZuoCollege of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China.
Jin LiuDepartment of Pharmaceutical Sciences, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. Electronic address: Jin.Liu@unthsc.edu.

Funding

Improvement of CRISPR-Cas9 specificity through allosteric modulationR15HL147265 · NHLBI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI LIU, JIN · 2019 to 2019
$438k
NHLBI NIH HHS R15 HL147265
6 · The paper itself

Abstract

The CRISPR-Cas9 system from Streptococcus pyogenes has been exploited as a programmable RNA-guided DNA-targeting and DNA-editing platform. This evolutionary tool enables diverse genetic manipulations with unprecedented precision and ease. Cas9 is an allosteric enzyme, which is allosterically regulated in conformational activation, target recognition, and DNA cleavage. Here, we outline the underlying allosteric control over the Cas9 complex assembly and targeting specificity. We further review the strategies for mitigating intrinsic Cas9 off-target effects through allosteric modulations and the advances in engineering controllable Cas9 systems that are responsive to external allosteric signals. Future development of highly specific, tunable CRISPR-Cas9 systems through allosteric modulations would greatly benefit applications that require both conditional control and high precision.

Indexed as

CRISPR-Cas SystemsAllosteric RegulationCRISPR-Associated Protein 9DNADNA CleavageHumansProtein EngineeringRNA, Guide, CRISPR-Cas SystemsCas9 endonuclease Streptococcus pyogenesCRISPR-Associated Protein 9DNARNA, Guide, CRISPR-Cas Systems

Identifiers

PMID32070859
PMCPMC7308215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.